<article>
<section>
<h1 id="header">Purification and cryoelectron microscopy structure determination of human V-ATPase</h1>
<p><time datetime="2021-02-19">Published: February 19, 2021</time></p>
<p>Longfei Wang,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#fn1">5</a>,<a href="#cor1">*</a></sup> Zhenhang Chen,<sup><a href="#aff3">3</a>,<a href="#aff4">4</a></sup> Hao Wu,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a></sup> and Tian-Min Fu<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff3">3</a>,<a href="#aff4">4</a>,<a href="#fn2">6</a>,<a href="#cor2">**</a></sup></p>
<p id="aff1"><sup>1</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA</p>
<p id="aff2"><sup>2</sup>Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, MA 02115, USA</p>
<p id="aff3"><sup>3</sup>Department of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH 43210, USA</p>
<p id="aff4"><sup>4</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA</p>
<p id="fn1"><sup>5</sup>Technical contact</p>
<p id="fn2"><sup>6</sup>Lead contact</p>
<p id="cor1"><sup>*</sup>Correspondence: <a href="mailto:wang@hkl.hms.harvard.edu">wang@hkl.hms.harvard.edu</a></p>
<p id="cor2"><sup>**</sup>Correspondence: <a href="mailto:fu.978@osu.edu">fu.978@osu.edu</a></p>
<p><span class="open-access">Open Access</span> • DOI: <a href="https://doi.org/10.1016/j.xpro.2021.100350">10.1016/j.xpro.2021.100350</a></p>
</section>
<section>
<h2 id="summary">Summary</h2>
<p>Vesicular- or vacuolar-type adenosine triphosphatases (V-ATPases) are multi-component, ATP-driven proton pumps, which play important roles in many physiological processes by acidifying intracellular vesicles, organelles, and the extracellular milieu. Long-standing challenges in purifying mammalian V-ATPases have limited the biochemical and structural study of mammalian V-ATPase. Here, we provide a protocol for purifying milligrams of human V-ATPase and detail procedures for the reconstruction of its structure by cryo-EM. Our method can be applied to any biochemical and biophysical study of human V-ATPase.</p>
<p>For complete details on the use and execution of this protocol, please refer to <a href="#bib10">Wang et al. (2020)</a>.</p>




<div class="highlights">
<h3>Highlights</h3>
<ul>
<li>Strategy to purify human V-ATPase from cultured human cells</li>
<li>Strategy to obtain homogeneous human V-ATPase using affinity purification</li>
<li>Purified human V-ATPase is sufficient for biochemical, biophysical, and structural study</li>
<li>Methods to obtain high-resolution structure of human V-ATPase by cryo-EM</li>
</ul>
</div>
<div class="graphical-abstract">
<h3>Graphical Abstract</h3>
<figure><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/476-GA.jpg" alt="GraphicalAbstract.jpg"></figure>
</div></section>
<section>
<h2 id="before-you-begin">Before you begin</h2>
<p>This protocol was used in a recent publication to purify a human V-ATPase and determine its structure by cryo-EM. Prior to the experiment, prepare all the buffers to be used one day in advance and make a recombinant plasmid containing <i>SidK</i>, which encodes a bacteria effector protein that can bind and inhibit the activity of human V-ATPase (<a href="#bib11">Xu et al., 2010</a>).</p>
<h3 id="sec1.1">Buffer preparation</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 1 day</div>
<ol>
<li>Buffer A<br> Prepare 1 L Buffer A containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 20 mM Imidazole.</li>
<li>Buffer B<br> Prepare 500 mL Buffer B containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 300 mM Imidazole.</li>
<li>Buffer C<br> Prepare 1 L Buffer C containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM tris(2-carboxyethyl) phosphine (TCEP).</li>
<li>Buffer D<br> Prepare 1 L buffer D containing 50 mM HEPES, pH 7.5, 50 mM NaCl.</li>
<li>Buffer E<br> 150 mM NaCl, 1 mM TCEP, 1% lauryl maltose neopentyl glycol (LMNG), 0.1% cholesteryl hemisuccinate (CHS), protease inhibitor cocktail (Sigma-Aldrich), and 50 mM HEPES at pH 7.4.</li>
<li>Buffer F<br> 150 mM NaCl, 1 mM TCEP, 0.1% lauryl maltose neopentyl glycol (LMNG), 0.01% cholesteryl hemisuccinate (CHS), and 50 mM HEPES at pH 7.4.</li>
<li>Buffer G<br> 150 mM NaCl, 1 mM TCEP, and 20 mM HEPES at pH 7.4.</li>
<li>Kanamycin stock<br> Prepare 10 mL Kanamycin stock with a concentration of 50 mg/mL.</li>
</ol>
<h3 id="sec1.2">Plasmid encoding the <i>SidK</i> gene</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 3 days</div>
<ol start="9">
<li>SidK was cloned into pET28a with an N-terminal His<sub>6</sub> tag and a Flag tag (<a href="#fig1">Figure 1</a>). The plasmid can be obtained from Dr. Fu through material transfer assignment.
<figure id="fig1"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/476-Fig1.jpg" alt="Fig1.jpg">
<figcaption>
<div class="figcaption-title">Figure 1. Schematic of the construct encoding N-terminal His6-Flag-tagged SidK</div>
<p>SidK (gray) was cloned into pET28a with an N-terminal His6 (purple) tag and a Flag (green) tag.</p>
</figcaption>
</figure>
</li>
</ol>
</section>
<section>
<h2 id="key-resources-table">Key resources table</h2>
<table id="krt">
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Chemicals, peptides, and recombinant proteins</td>
</tr>
<tr>
<td>Freestyle 293 medium</td>
<td>GIBCO</td>
<td>Cat# 12338-018</td>
</tr>
<tr>
<td>Fetal bovine serum (FBS)</td>
<td>GIBCO</td>
<td>Cat# 16000-044</td>
</tr>
<tr>
<td>Lauryl maltose neopentyl glycol (LMNG)</td>
<td>Anatrace</td>
<td>Cat# NG310</td>
</tr>
<tr>
<td>Cholesteryl hemisuccinate (CHS)</td>
<td>Anatrace</td>
<td>Cat# CH210</td>
</tr>
<tr>
<td>Kanamycin</td>
<td>Goldbio</td>
<td>Cat# K-120</td>
</tr>
<tr>
<td>IPTG</td>
<td>Goldbio</td>
<td>Cat# 12481</td>
</tr>
<tr>
<td>Glycerol</td>
<td>Fisher Scientific</td>
<td>Cat# G33500</td>
</tr>
<tr>
<td>Protease inhibitor cocktail tablets</td>
<td>Millipore-Sigma</td>
<td>Cat# S8830</td>
</tr>
<tr>
<td>Antibiotic-antimyocotic (anti-anti)</td>
<td>Thermo Fisher</td>
<td>Cat # 15240-062</td>
</tr>
<tr>
<td>3X FLAG peptide</td>
<td>Millipore-Sigma</td>
<td>Cat # F4799</td>
</tr>
<tr>
<td>Tris(2-carboxyethyl) phosphine hydrochloride (TCEP)</td>
<td>Goldbio</td>
<td>Cat # 51805-45-9</td>
</tr>
<tr>
<td colspan="3">Critical commercial assays</td>
</tr>
<tr>
<td>Superdex 200, 10/300 GL</td>
<td>GE Healthcare</td>
<td>Cat# 17-5175-01</td>
</tr>
<tr>
<td>Ni-NTA agarose</td>
<td>QIAGEN</td>
<td>Cat# 30230</td>
</tr>
<tr>
<td>ANTI-FLAG M2 affinity gel</td>
<td>Millipore-Sigma</td>
<td>Cat# A2220</td>
</tr>
<tr>
<td>Amicon Ultra 10K MWCO centrifugal filter unit</td>
<td>Millipore-Sigma</td>
<td>Cat# UFC8010</td>
</tr>
<tr>
<td>Amicon Ultra 50K MWCO centrifugal filter unit</td>
<td>Millipore-Sigma</td>
<td>Cat# UFC8050</td>
</tr>
<tr>
<td colspan="3">Deposited data</td>
</tr>
<tr>
<td>V-ATPase (state 1) density map</td>
<td>This study</td>
<td>EMD-21847</td>
</tr>
<tr>
<td>V-ATPase (state 1) atomic model</td>
<td>This study</td>
<td>PDB 6WM2</td>
</tr>
<tr>
<td>V1 density map</td>
<td>This study</td>
<td>EMD-21845</td>
</tr>
<tr>
<td>V1 atomic model</td>
<td>This study</td>
<td>PDB 6WLZ</td>
</tr>
<tr>
<td>V<sub>o</sub> density map</td>
<td>This study</td>
<td>EMD-21844</td>
</tr>
<tr>
<td>V<sub>o</sub> atomic model</td>
<td>This study</td>
<td>PDB 6WLW</td>
</tr>
<tr>
<td>V-ATPase (state 2) density map</td>
<td>This study</td>
<td>EMD-21848</td>
</tr>
<tr>
<td>V-ATPase (state 2) atomic model</td>
<td>This study</td>
<td>PDB 6WM3</td>
</tr>
<tr>
<td>V-ATPase (state 3) density map</td>
<td>This study</td>
<td>EMD-21849</td>
</tr>
<tr>
<td>V-ATPase (state 3) atomic model</td>
<td>This study</td>
<td>PDB <a href="http://www.rcsb.org/pdb/explore.do?structureId=6V01">6WM4</a>
</td>
</tr>
<tr>
<td colspan="3">Experimental models: cell lines</td>
</tr>
<tr>
<td>HEK293S GnTI<sup>-</sup>
</td>
<td>ATCC</td>
<td>Cat# CRL-3022</td>
</tr>
<tr>
<td colspan="3">Recombinant DNA</td>
</tr>
<tr>
<td>SidK (14-273)</td>
<td>pET28a</td>
<td>N/A</td>
</tr>
<tr>
<td colspan="3">Software and algorithms</td>
</tr>
<tr>
<td>SerialEM</td>
<td>(<a href="#bib4">Mastronarde, 2005</a>)</td>
<td><a href="http://bio3d.colorado.edu/SerialEM">http://bio3d.colorado.edu/SerialEM</a></td>
</tr>
<tr>
<td>RELION</td>
<td>(<a href="#bib8">Scheres, 2012</a>)</td>
<td><a href="https://www2.mrc-lmb.cam.ac.uk/relion">https://www2.mrc-lmb.cam.ac.uk/relion</a></td>
</tr>
<tr>
<td>UCSF Chimera</td>
<td>(<a href="#bib5">Pettersen et al., 2004</a>)</td>
<td><a href="http://www.cgl.ucsf.edu/chimera">http://www.cgl.ucsf.edu/chimera</a></td>
</tr>
<tr>
<td>PHENIX</td>
<td>(<a href="#bib1">Adams et al., 2010</a>)</td>
<td><a href="https://www.phenix-online.org">https://www.phenix-online.org</a></td>
</tr>
<tr>
<td>COOT</td>
<td>(<a href="#bib3">Emsley and Cowtan, 2004</a>)</td>
<td><a href="http://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">http://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</a></td>
</tr>
<tr>
<td>PyMOL</td>
<td>Molecular Graphics System, Version 1.8 Schrodinger</td>
<td><a href="http://www.pymol.org/">http://www.pymol.org</a></td>
</tr>
<tr>
<td colspan="3">Other</td>
</tr>
<tr>
<td>400 mesh Lacey carbon grids</td>
<td>Electron Microscopy Sciences</td>
<td>Cat# LC400-Cu-CC</td>
</tr>
<tr>
<td>FEI Vitrobot Mark IV</td>
<td>Thermo Fisher Scientific</td>
<td>NA</td>
</tr>
</tbody>
</table>
</section>
<section>
<h2 id="step-by-step-method-details">Step-by-step method details</h2>
<p>Below we provide details about the purification and structure reconstruction of human V-ATPase (<a href="#fig2">Figure 2</a>).</p>
<figure id="fig2"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/476-Fig2.jpg" alt="Fig2.jpg">
<figcaption>
<div class="figcaption-title">Figure 2. Schematic of the workflow in this protocol</div>
</figcaption>
</figure>
<h3 id="sec2.1">Expression and purification of flag-tagged Sidk protein</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 4–5 days</div>
<p>Purify the flag-tagged SidK protein, which will be used as an affinity bait for the purification of human V-ATPase (<a href="#fig3">Figure 3</a>A).</p>
<figure id="fig3"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/476-Fig3.jpg" alt="Fig3.jpg">
<figcaption>
<div class="figcaption-title">Figure 3. Purification of SidK</div>
<p>(A) The workflow for the purification of SidK.</p>
<p>(B) The purified SidK on SDS-PAGE.</p>
</figcaption>
</figure>
<ol>
<li>Expression of flag-tagged SidK in <i>E. coli</i>
<ol type="a">
<li>Transform the recombinant plasmid of pET28a containing flag-tagged SidK into <i>E. coli</i> BL21(DE3) RIPL and grow single colonies on an LB plate with 50 μg/mL Kanamycin.</li>
<li>Inoculate a single colony to 25 mL LB broth with 50 μg/mL Kanamycin for overnight culture at 37°C with shaking at 200 rpm.</li>
<li>The 25 mL culture was diluted into 1 L LB broth with 50 μg/mL Kanamycin for further growing at 37°C with shaking at 200 rpm to a density of OD ~0.6.</li>
<li>Add 0.5 mM IPTG to the culture for the induction of protein expression at 18°C for 16–20 h.</li>
<li>Harvest the cultured cells by centrifugation at 180 rcf for 10 min.</li>
</ol>
</li>
<li>Purification of flag-tagged SidK
<ol type="a">
<li>The harvested cells were resuspended in 30 mL buffer A containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 20 mM Imidazole that was pre-cold at 4°C.</li>
<li>The cells were disrupted by sonication (50% power, 5 s on, 5 s off) for 4 min on ice.</li>
<li>The cell lysate was centrifuged at 20,000 rcf for 40 min to remove cell debris.</li>
<li>After centrifugation, the supernatant was incubated with 1 mL Ni-NTA resin pre-equilibrated by buffer A at 4°C for 30 min.</li>
<li>The resin was then washed with 10 mL buffer A containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 20 mM Imidazole.</li>
<li>The protein was eluted using 4 mL buffer B containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 300 mM Imidazole.</li>
<li>The eluted flag-tagged SidK was further purified by gel filtration in buffer C containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM TCEP.</li>
<li>Analyze the purity of the protein by SDS-PAGE (<a href="#fig3">Figure 3</a>B).</li>
<li>Pool the protein fractions and concentrate to 2 mg/mL using spin filter concentrator (Company). Protein concentration was quantified by measuring the UV280 absorbance using NanoDrop Spectrophotometer (Thermo Fisher Scientific).</li>
<li>Freeze 100 μL aliquots of SidK protein in liquid nitrogen and store the protein in −80°C freezer.</li>
</ol>
</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> During the wash step in step 2e, up to 20 mL buffer A may be used to wash the resin, which will help to maximally eliminate non-specific bound proteins.</div>
<h3 id="sec2.2">Purification of human V-ATPase</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2–3 weeks</div>
<p>Purify human V-ATPase from HEK293S cells by affinity purification and glycerol gradient ultracentrifugation (<a href="#fig4">Figure 4</a>A).</p>
<figure id="fig4"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/476-Fig4.jpg" alt="Fig4.jpg">
<figcaption>
<div class="figcaption-title">Figure 4. Purification of human V-ATPase</div>
<p>(A) The workflow for the purification of human V-ATPase.</p>
<p>(B) The purified human V-ATPases on SDS-PAGE.</p>
</figcaption>
</figure>
<ol start="3">
<li>293S cell culture
<ol type="a">
<li>One vial of frozen 293S cells were diluted into 25 mL Freestyle 293 medium for centrifugation at 180 rcf for 5 min.</li>
<li>The cell pellets were resuspended using 30 mL fresh medium of Freestyle 293 medium supplemented with 10% FBS and 1% antibiotics-antimycotic (anti-anti) in a 200 mL Baffled flask and cultured at 37°C with shaking at 100 rpm in a mammalian cell culture shaker.</li>
<li>The cells were diluted into 1.0 million/mL using fresh Freestyle 293 medium with 1% anti-anti when the cell density arrived at 2.0 million/mL to prepare 5 L 293F cell culture.</li>
<li>293S cells were harvested by centrifugation at 180 rcf for 10 min.</li>
</ol>
</li>
<li>V-ATPase Purification
<ol type="a">
<li>Isolation of Membrane Fraction
<ol type="i">
<li>The harvested cells were resuspended in 150 mL buffer D containing 50 mM HEPES, pH 7.5, 50 mM NaCl supplemented with protease inhibitor cocktail and incubated for 2 h on ice.</li>
<li>The cells were further disrupted by hand-driven Dounce homogenization (PYREX, Corning).</li>
<li>The cell lysate was centrifuged at 20,000 rcf for 30 min to remove cell debris.</li>
<li>The supernatant was centrifugated at 200, 000 rcf in a Type 45 Ti rotor (Beckman) for 1 h to obtain the membrane pellet.</li>
</ol>
</li>
<li>Purification of V-ATPase by anti-Flag Resin
<ol type="i">
<li>The membrane pellet was resuspended in the buffer E containing 150 mM NaCl, 1 mM TCEP, 1% lauryl maltose neopentyl glycol (LMNG), 0.1% cholesteryl hemisuccinate (CHS), protease inhibitor cocktail (Sigma-Aldrich), and 50 mM HEPES at pH 7.4 and homogenized using a hand-driven Dounce homogenizer (PYREX, Corning).</li>
<li>The homogenized membrane solution was mixed with 0.1 mg flag-tagged SidK protein and incubated for 4 h at 4°C.</li>
<li>After incubation, the mixture was centrifuged at 20,000 rcf for 30 min to remove insoluble material.</li>
<li>Supernatant containing solubilized V-ATPase/SidK complex was then incubated with 1 mL anti-Flag resin for 1 h at 4°C.</li>
<li>The resin was collected and washed with 10 mL buffer F containing 150 mM NaCl, 1 mM TCEP, 0.1% lauryl maltose neopentyl glycol (LMNG), 0.01% cholesteryl hemisuccinate (CHS), and 50 mM HEPES at pH 7.4</li>
<li>The V-ATPase/SidK complex was eluted using 5 mL wash buffer F plus 100 μg/mL 3X FLAG peptide.</li>
</ol>
</li>
<li>Further Purification of V-ATPase by Glycerol Gradient Ultracentrifugation
<ol type="i">
<li>Prepare 1 mL each of 15%, 30%, 45%, and 60% glycerol solutions in buffer G plus 0.001% lauryl maltose neopentyl glycol (LMNG) and 0.0001% cholesteryl hemisuccinate CHS.</li>
<li>Prepare glycerol gradient by gently injecting 1 mL 15%, 30%, 45%, and 60% glycerol solutions to the bottom of a polyclear centrifuge tube using a 1 mL syringe.</li>
<li>Slowly load between 100 μL and 500 μL V-ATPase fraction from previous step on top of the glycerol gradient.</li>
<li>Balance the two tubes before loading them into the swing-out rotor.</li>
<li>Centrifuge at 171,520 rcf in a Beckman MLS-50 rotor and Beckman Optima MAX ultracentrifuge for 20 h at 4°C.</li>
<li>After centrifugation, manually fractionate by poking a hole at the bottom of the centrifuge tube and collect the first 16 fractions of 250 μL each.</li>
<li>Analyze each fraction by SDS-PAGE to select the fractions with intact V-ATPase (<a href="#fig4">Figure 4</a>B). The V-ATPase concentration was quantified by NanoDrop Spectrophotometer (Thermo Fisher Scientific).</li>
</ol>
</li>
</ol>
</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> The Freestyle 293 medium needs to be pre-warmed to 37°C before use.</div>
<div class="note">
<span class="note-title">Note:</span> Make sure to add sufficient amount of protease inhibitor to avoid protein degradation by endogenous protease during cell lysis and protein purification processes.</div>
<div class="critical">
<span class="critical-title">Critical:</span> When you load the glycerol into the centrifuge tube, be careful to avoid air bubbles and not to disturb the interface.</div>
<div class="critical">
<span class="critical-title">Critical:</span> Avoid boiling samples for SDS-PAGE, otherwise the protein complex will form large aggregates that are difficult to enter the gel.</div>
<div class="pause-point">
<span class="pause-point-title">Pause Point:</span> The harvested cells in step 3 or the isolated membrane pellets in step 4a may be stored in −80°C freezer for up to a month before moving on to the next steps.</div>
<h3 id="sec2.3">Grids preparation and cryo-EM data collection</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2–4 days</div>
<p>Prepare cryo-EM grids of human V-ATPase and collect cryo-EM data for structure reconstruction (<a href="#fig5">Figure 5</a>).</p>
<figure id="fig5"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/476-Fig5.jpg" alt="Fig5.jpg">
<figcaption>
<div class="figcaption-title">Figure 5. Grid preparation and data collection</div>
<p>(A) The workflow for grids preparation and data collection.</p>
<p>(B) A representative cryo-EM image of human V-ATPase.</p>
</figcaption>
</figure>
<ol start="5">
<li>Grid Preparation
<ol type="a">
<li>Copper grids with less than 3 nm continuous ultrathin carbon and lacey carbon support film was glow-discharged for 1 min at the current of 30 mA.</li>
<li>A 3 μL drop of purified human V-ATPase sample was applied to the glow-discharged grids and incubated at 4°C for 10 min.</li>
<li>The grids were washed for three times using 5 μL buffer G containing 20 mM HEPES at pH 7.5 and 150 mM NaCl to remove the glycerol as much as possible.</li>
<li>The grids were blotted using standard vitrobot filter paper (Ted Pella) for 4 s with force of 5 in 100% humidity at 4°C, and plunged into liquid ethane using an FEI Vitrobot Mark IV.</li>
</ol>
</li>
<li>Cryo-EM Data Collection
<ol type="a">
<li>Grids screening
<ol type="i">
<li>All the grids were clipped</li>
<li>The clipped grids were loaded to FEI Talos Arctica microscope for screening.</li>
<li>The grids with good ice and particle distribution were saved for data collection (<a href="#fig5">Figure 5</a>B).</li>
</ol>
</li>
<li>Data collection
<ol type="i">
<li>Grids for data collection were loaded to FEI Titan Krios microscope with a K3 detector and energy filter.</li>
<li>Data were collected in counting mode, with 40 total frames per movie in 3.2 s, a total dose of 50 electrons per Å<sup>2</sup>, a physical pixel size of 1.08 Å, and defocus values between 1 nm to 3 nm.</li>
</ol>
</li>
</ol>
</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> As the protein concentration is relatively low for preparing cryo-grids, we therefore choose carbon-coated grids that help to concentrate protein particles on the grids.</div>
<div class="critical">
<span class="critical-title">Critical:</span> During grids preparation, the elimination of glycerol in samples by washing three times is critical for preparing girds with proper ice.</div>
<div class="pause-point">
<span class="pause-point-title">Pause Point:</span> The prepared grids in step 5 may be stored in liquid nitrogen for screening and data collection.</div>
<h3 id="sec2.4">Cryo-EM data processing</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2–3 weeks</div>
<p>Process cryo-EM data to obtain cryo-EM density maps of human V-ATPase (<a href="#fig6">Figure 6</a>).</p>
<figure id="fig6"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/476-Fig6.jpg" alt="Fig6.jpg">
<figcaption>
<div class="figcaption-title">Figure 6. Schematics of structure determination</div>
</figcaption>
</figure>
<ol start="7">
<li>Beam-induced motion correction<br> Motion correction was done in RELION by the implementation of UCSF MOTIONCOR2(<a href="#bib12">Zheng et al., 2017</a>, <a href="#bib8">Scheres, 2012</a>).</li>
<li>CTF estimation<br> Contrast transfer function (CTF) estimation was done by CTFFIND4.1 in RELION (<a href="#bib8">Scheres, 2012</a>, <a href="#bib7">Rohou and Grigorieff, 2015</a>).</li>
<li>Initial Particle Picking<br> The particle picking was done using a template-free auto-picking procedure based on a Laplacian-of-Gaussian filter to select an initial set of particles (<a href="#bib9">Wagner et al., 2019</a>).</li>
<li>2D Classification<br> The selected particles were used in a 2D classification to generate templates for a second round of auto-picking job.</li>
<li>Second round particle picking<br> The particle picking was done by Gautomatch using the templates generated in step 10 as references.</li>
<li>2D Classification<br> Total 782,583 particles were picked for 2D classification to select good classes for further 3D classification.</li>
<li>3D Classification<br> The selected particles were 3D-classified into 6 classes and 3 classes out of the 6 are corresponding to the 3 states of the V-ATPase.</li>
<li>3D refinement<br> The 3 states were selected for non-uniform 3D refinement in cryoSPARC (<a href="#bib6">Punjani et al., 2017</a>). The 3D reconstruction resulted in three maps with resolutions of 3.1 Å, 3.4 Å, and 3.6 Å, respectively.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Regularization parameter Ts for 2D classification (step 12) and 3D classification (step 13) are 2 and 4, respectively.</div>
<h3 id="sec2.5">Model building and refinement</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2–4 weeks</div>
<p>Based on the cryo-EM maps we obtained above, we built atomic models of human V-ATPase.</p>
<ol start="15">
<li>Model Building<br> The initial structure model of human V-ATPase was generated using SWISS-MODEL based on yeast V-ATPase and fitted as rigid bodies into cryo-EM maps using Chimera (<a href="#bib2">Biasini et al., 2014</a>, <a href="#bib5">Pettersen et al., 2004</a>). The structures were further manually adjusted in coot (<a href="#bib3">Emsley and Cowtan, 2004</a>).</li>
<li>Refinement<br> Real-space refinement was performed using PHENIX following the routine protocol and the models were validated by PHENIX (<a href="#bib1">Adams et al., 2010</a>).</li>
</ol>
</section>
<section>
<h2 id="expected-outcomes">Expected outcomes</h2>
<p>From 5 L human 293S cells, about 0.05 mg human V-ATPase was purified as estimated by A280 using nanodrop (<a href="#fig4">Figure 4</a>B). The purified protein can be used for biochemical and biophysical studies related to V-ATPase. Furthermore, structures of human V-ATPase can be used for drug design and computational biology (<a href="#fig6">Figure 6</a>).</p>
</section>
<section>
<h2 id="limitations">Limitations</h2>
<p>Due to the low expression level of endogenous V-ATPase, you need large-scale culture of 293S cells for one purification prep.</p>
</section>
<section>
<h2 id="troubleshooting">Troubleshooting</h2>
<h3 id="sec5.1">Problem 1</h3>
<p>The particle density on the prepared grids might not be high enough for data collection.(Step 5)</p>
<h3 id="sec5.2">Potential solution</h3>
<p>Repeat step 5b once before proceeding to step 5c.</p>
</section>
<section>
<h2 id="references">References</h2>
<p id="bib1">Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. <i>66</i>, 213-221. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref1">View at publisher</a></p>
<p id="bib2">Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Cassarino, T.G., Bertoni, M., Bordoli, L., and Schwede, T. (2014). SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. <i>42</i>, W252-W258. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref2">View at publisher</a></p>
<p id="bib3">Emsley, P. and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. <i>60</i>, 2126-2132. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref3">View at publisher</a></p>
<p id="bib4">Mastronarde, D.N. (2005). Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. <i>152</i>, 36-51. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref4">View at publisher</a></p>
<p id="bib5">Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. <i>25</i>, 1605-1612. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref5">View at publisher</a></p>
<p id="bib6">Punjani, A., Rubinstein, J.L., Fleet, D.J., and Brubaker, M.A. (2017). cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods <i>14</i>, 290-296. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref6">View at publisher</a></p>
<p id="bib7">Rohou, A. and Grigorieff, N. (2015). CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. <i>192</i>, 216-221. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref7">View at publisher</a></p>
<p id="bib8">Scheres, S.H. (2012). RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. <i>180</i>, 519-530. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref8">View at publisher</a></p>
<p id="bib9">Wagner, T., Merino, F., Stabrin, M., Moriya, T., Antoni, C., Apelbaum, A., Hagel, P., Sitsel, O., Raisch, T., Prumbaum, D., Quentin, D., Roderer, D., Tacke, S., Siebolds, B., Schubert, E., Shaikh, T.R., Lill, P., Gatsogiannis, C., and Raunser, S. (2019). SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun. Biol. <i>2</i>, 218. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref9">View at publisher</a></p>
<p id="bib10">Wang, L., Wu, D., Robinson, C.V., Wu, H., and Fu, T.M. (2020). Structures of a complete human V-ATPase reveal mechanisms of its assembly. Mol. Cell <i>80</i>, 501-511.e3. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref10">View at publisher</a></p>
<p id="bib11">Xu, L., Shen, X., Bryan, A., Banga, S., Swanson, M.S., and Luo, Z.Q. (2010). Inhibition of host vacuolar H+-ATPase activity by a <i>Legionella pneumophila</i> effector. PLoS Pathog. <i>6</i>, e1000822. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref11">View at publisher</a></p>
<p id="bib12">Zheng, S.Q., Palovcak, E., Armache, J.P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods <i>14</i>, 331-332. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00057-5/sref12">View at publisher</a></p>
</section>
<section>
<h2 id="article-info">Article Info</h2>
<h3>Resource Availability</h3>
<h4>Lead Contact</h4>
<p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Tian-Min Fu (<a href="mailto:fu.978@osu.edu">fu.978@osu.edu</a>).</p>
<h4>Materials Availability</h4>
<p>Plasmids generated in this study are available upon request from the lead contact with a completed Material Transfer Agreement.</p>
<h4>Data and Code Availability</h4>
<p>The cryo-EM maps included in this study have been deposited in the Electron Microscopy Data Bank with accession codes: EMD-21844, EMD-21845, EMD-21847, EMD-21848, and EMD-21849. The atomic coordinates have been deposited in the Protein Data Bank with accession codes: 6WM2, 6WM3, 6WM4, 6WLZ, and 6WLW.</p>
<h3>Acknowledgments</h3>
<p>Cryo-EM grid screening was performed with the assistance of Richard Walsh, Sarah Sterling, and Shaun Rawson at the Harvard Cryo-Electron Microscopy Center for Structural Biology supported by grants from the <a href="https://doi.org/10.13039/100000057">National Institute of General Medical Sciences</a> (GM103310). The cryo-EM dataset was collected by Ulrich Baxa, Adam D. Wier, and Thomas J. Edwards at the <a href="https://doi.org/10.13039/100000054">National Cancer Institute</a>’s National Cryo-EM Facility, <a href="https://doi.org/10.13039/100012728">Frederick National Laboratory for Cancer Research</a> under contract HSSN261200800001E. Tandem mass spectrometry was performed by Ross Tomaino and Christopher Jahns at Taplin Mass Spectrometry Facility. L.W. was supported by funding from an <a href="https://doi.org/10.13039/100000002">NIH</a> T32 grant (5T32AI007512-34). T.-M.F. was supported by funding from an NIH T32 grant (5T32HL066987-18) and by start-up funds from the Ohio State University Comprehensive Cancer Center.</p>
<h3>Author Contributions</h3>
<p>T.-M.F., L.W., and H.W. conceived the project. L.W., T.M.F., and Z.C. performed the experiments. T.-M.F. wrote the manuscript with input from all authors.</p>
<h3>Declaration of Interests</h3>
<p>H.W. is a member of scientific advisory board of <i>Cell</i>. The other authors declare no competing interests.</p>
</section>
</article>